467 results
6-K
EX-99.2
SNY
Sanofi
2 May 24
Current report (foreign)
3:52pm
underscore the potential for rilzabrutinib to deliver clinically meaningful benefits for patients living with persistent and chronic ITP.
Rilzabrutinib
6-K
EX-99.4
SNY
Sanofi
2 May 24
Current report (foreign)
3:52pm
% of the economic benefits in its Business Operating Income.
Beyfortus has been approved for use in the European Union, the US, China, Japan, and many
6-K
EX-99.1
SNY
Sanofi
25 Apr 24
Sales growth of 6.7% at CER and business EPS(1) of €1.78
10:49am
. It provides social, emotional and financial support and secures the job, salary and benefits of any employee for up to twelve months, no matter … in provisions including pensions and other post-employment benefits, deferred taxes, share-based expense and other non-cash items. It comprises net
F-3ASR
SNY
Sanofi
4 Apr 24
Automatic shelf registration (foreign)
2:07pm
entitled to benefits under that convention generally will not be subject to French gift or inheritance tax, so long as the donor or decedent
F-3ASR
EX-1.1
SNY
Sanofi
4 Apr 24
Automatic shelf registration (foreign)
2:07pm
, and will be entitled to the benefits of the Indenture.
(l) Underwriting Agreement. The Underwriting Agreement has been duly authorized, executed and delivered … as practicable an earning statement that satisfies Rule 158 of the Securities Act for the purposes of, and to provide the Underwriters the benefits
F-3ASR
EX-4.1
bk6b1d s5fyf6cs2
4 Apr 24
Automatic shelf registration (foreign)
2:07pm
F-3ASR
EX-25.1
en8 gs9p9
4 Apr 24
Automatic shelf registration (foreign)
2:07pm
6-K
EX-99.1
lhkg 8pgozmvy04u
15 Feb 24
Current report (foreign)
12:09pm
6-K
EX-99.1
svc7cjbw n3h0
1 Feb 24
Sanofi Delivers Solid Sales and Business EPS Growth at CER Amidst Successful Product Launches and Advancements in Immunology Pipeline
9:45am
6-K
EX-99.1
wye31qiaa
23 Jan 24
Sanofi to acquire Inhibrx, Inc., adding potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency to pipeline
7:23am
F-6EF
EX-99
8habpm7x
18 Dec 23
Automatic registration for ADRs (foreign)
5:23pm
6-K
EX-99.1
g1fe qiv8hv
27 Oct 23
Specialty Care growth, strong launch uptake of Beyfortus® and ALTUVIIIO® drive solid Q3 results
12:39pm
6-K
EX-99.2
mibznc1dbl6r
11 Oct 23
Sanofi announces agreement for potential first-in-class vaccine against extraintestinal pathogenic E. coli
6:05am
6-K
EX-99.1
ws4you21z
27 Sep 23
Current report (foreign)
6:06am
6-K
EX-99.1
zzw5i9m
10 Aug 23
Recommendation for use in all infants below 8 months of age follows earlier than anticipated FDA approval and unanimous FDA Advisory Committee vote
9:50am
6-K
EX-99.1
o2a0b
28 Jul 23
Solid Q2 performance and strong pipeline momentum
3:35pm
6-K
EX-99.1
wzay2bzo4jz3h
28 Jul 23
Condensed Half-year Consolidated Financial Statements
7:00am
6-K
EX-99.2
3ynfl8942
28 Jul 23
Condensed Half-year Consolidated Financial Statements
7:00am
6-K
EX-99.1
e4j k7jhwhzurg
24 Jul 23
FDA approves Beyfortus™ (nirsevimab-alip) to protect infants against RSV disease
12:43pm
11-K
uxosyi8
28 Jun 23
Annual report of employee stock purchases
2:32pm